Akero Therapeutics shares are trading higher after the company reported its SYMMETRY study met safety and tolerability endpoints.
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics reported that its SYMMETRY study met safety and tolerability endpoints, leading to higher trading of its shares.
June 05, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akero Therapeutics' SYMMETRY study met safety and tolerability endpoints, resulting in higher trading of its shares.
The positive results from Akero Therapeutics' SYMMETRY study indicate that the company has achieved a significant milestone in its product development. This news is likely to boost investor confidence in the company's potential, leading to higher trading of its shares in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100